IP Library Granted Patent US 9,233,143
Granted Patent B2
US 9,233,143 · App. 14/239,301 · Granted Jan 12, 2016

Medicinal agent for preventing exacerbation of malignant tumor, comprising combination of natriuretic peptide receptor GC-A and GC-B agonists

Inventors: Kenji Kangawa (Osaka, JP); Hiroshi Hosoda (Osaka, JP); Takashi Nojiri (Osaka, JP); Meinoshin Okumura (Osaka, JP); Mayumi Furuya (Kobe, JP)
Assignees: National Cerebral and Cardiovascular Center; Osaka University; Shionogi & Co., Ltd.
A61K38/22A61K38/2242A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,233,143
App. No.
14/239,301
Granted
Jan 12, 2016
Kind
B2
Abstract

Provided are a medicinal agent which is highly safe for use as the treatment of a malignant tumor and is capable of efficiently treating a malignant tumor, that is, a medicinal agent for treating a malignant tumor or for suppressing or preventing the exacerbation thereof, comprising at least one kind of natriuretic peptide receptor GC-A agonist and at least one kind of natriuretic peptide receptor GC-B agonist to be administered in combination; a therapeutic method comprising administering the agent; etc.

Claims (5)

1. A method for treating a malignant tumor or for suppressing or preventing the exacerbation thereof, comprising administering an effective amount of an atrial natriuretic peptide consisting of the amino acid sequence of SEQ ID NO: 1and an effective amount of a c-type natriuretic peptide consisting of the amino acid sequence of SEQ ID NO: 7 in combination, wherein the effective amount of atrial natriuretic peptide is 0.01 μg kg −1 min −1 or more and 0.2 μg kg −1 min −1 or less and the effective amount of c-type natriuretic peptide is 0.01 μg kg −1 min −1 or more and 1.0 μg kg −1 min −1 or less, and wherein the effective amount is administered continuously for at least three days.

2. The method according to claim 1 , wherein the atrial natriuretic peptide and the c-type natriuretic peptide are administered simultaneously.

3. The method according to claim 1 , wherein the atrial natriuretic peptide and the c-type natriuretic peptide are administered in a single formulation.

4. A method for treating a malignant tumor or for suppressing or preventing the exacerbation thereof, which comprises administering an agent which comprises atrial natriuretic peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient at an amount which is 0.01 μg kg −1 min −1 or more and 0.2 μg kg −1 min −1 or less and the agent is administered in combination with a c-type natriuretic peptide consisting of the amino acid sequence of SEQ ID NO: 7 at an amount which is 0.01 μg kg −1 min −1 or more and 1.0 μg kg −1 min −1 or less and wherein the agent and c-natriuretic peptide are administered continuously for at least three days.

5. A method for treating a malignant tumor or for suppressing or preventing the exacerbation thereof, the method comprising administering a medicinal agent which comprises a c-type natriuretic peptide consisting of the amino acid sequence of SEQ ID NO: 7 as an active ingredient at an amount which is 0.01 μg kg −1 min −1 or more and 1.0 μg kg −1 min −1 or less and said medicinal agent is to be administered in combination with an atrial natriuretic peptide consisting of the amino acid sequence of SEQ ID NO: 1 at an amount which is 0.01 μg kg −1 min −1 or more and 0.2 μg kg −1 min −1 or less and wherein the medicinal agent and atrial natriuretic peptide are administered continuously for at least three days.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2015
From: DAIICHI SANKYO COMPANY, LIMITED
To: SHIONOGI & CO., LTD.
Reel/Frame 035286/0210 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2014
From: KANGAWA, KENJI; HOSADA, HIROSHI; NOJIRI, TAKASHI; OKUMURA, MEINOSHIN; FURUYA, MAYUMI
To: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER; OSAKA UNIVERSITY; DAIICHI SANKYO COMPANY, LIMITED
Reel/Frame 032870/0353 →
Priority Claims (1)
JP 2011-179751 · Aug 19, 2011 · national
Continuity (1)
Related Publication 20140248269A1 · Sep 4, 2014